相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1
G. M. Haag et al.
EUROPEAN JOURNAL OF CANCER (2018)
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg et al.
NATURE MEDICINE (2018)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment
Giulia Chiaruttini et al.
ONCOIMMUNOLOGY (2017)
Evolution of Salmonella Typhi outer membrane protein-specific T and B cell responses in humans following oral Ty21a vaccination: A randomized clinical trial
Juan Manuel Carreno et al.
PLOS ONE (2017)
Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
Yukinori Ozaki et al.
BMC CANCER (2017)
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
S. Diem et al.
BRITISH JOURNAL OF CANCER (2016)
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Kelly D. Moynihan et al.
NATURE MEDICINE (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
Eric F. Zhu et al.
CANCER CELL (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Tumor-infiltrating lymphocytes for the treatment of metastatic cancer
M. H. Geukes Foppen et al.
MOLECULAR ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
Sander Kelderman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
Ester Simeone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Tumor infiltrating B-cells are increased in prostate cancer tissue
Jason R. Woo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
J. Delyon et al.
ANNALS OF ONCOLOGY (2013)
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer
Rin Yamaguchi et al.
HUMAN PATHOLOGY (2012)
Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients
Serena S. Kwek et al.
JOURNAL OF IMMUNOLOGY (2012)
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin et al.
NATURE METHODS (2012)
TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients
Pia Kvistborg et al.
ONCOIMMUNOLOGY (2012)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies
Amy E. Gilbert et al.
PLOS ONE (2011)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cutaneous Melanoma Is Related to Immune Suppression in Kidney Transplant Recipients
Claire M. Vajdic et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Spontaneous regression of metastases from melanoma: review of the literature
Louise Vennegaard Kalialis et al.
MELANOMA RESEARCH (2009)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
ID Davis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
MJ Scanlan et al.
IMMUNOLOGICAL REVIEWS (2002)
Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy
VH Engelhard et al.
IMMUNOLOGICAL REVIEWS (2002)
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations
Y Nagata et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
